This model contains a biallelic deletion of the metabotropic glutamate receptor 5 (mGluR5 or Grm5). mGluR5 function is altered in Fragile X syndrome, and mGluR5 has emerged as a promising drug target for both Fragile X syndrome and autism spectrum disorders.
• mGluR5 is implicated in the neuropharmacology of cognition, anxiety, addiction and pain • The function of this receptor is altered in Fragile X syndromem • GlurR5 antagonists are being pursued as potential therapeutics for Fragile X syndrome and autism spectrum disorders • Background Strain: Sprague-Dawley
Figure 1: mGluR5 knockout rats lack mGluR5 protein as determined by Western blot. Actin bands demonstrate equal sample loading.